Literature DB >> 6208034

A monoclonal antibody against a CEA-related antigen expressed on HT29 colon tumour cells.

G T Rogers, G A Rawlins, A Kardana, A R Gibbons, K D Bagshawe.   

Abstract

A new monoclonal antibody, that binds to CEA and with low cross-reactivity with NCA, has been raised to an antigen expressed on HT29 colon tumour cells. This antibody (H58) reacts strongly with high-molecular-weight protein (50 X 10(4)) isolated from a crude plasma membrane preparation of HT29 cells as well as binding to purified CEA of molecular size (20 X 10(4)) isolated both from those cells and liver metastases of colon tumour. H58 binds to an epitope sterically unrelated to the binding site of the previously described anti-CEA monoclonal antibody MA/1 and our routine anti-CEA polyclonal serum PKIG. Augmented binding of antibody to either the cell membrane preparation or conventional CEA can be achieved using a mixture comprising equal weights of specific immunoglobulin from H58 and MA/1. The value of solid-phase binding assays using microtitre plates for selecting potentially useful antibodies is discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6208034     DOI: 10.1016/0277-5379(84)90257-8

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  2 in total

1.  Mapping epitope characteristics on carcinoembryonic antigen.

Authors:  P J Harwood; D W Britton; P J Southall; G M Boxer; G Rawlins; G T Rogers
Journal:  Br J Cancer       Date:  1986-07       Impact factor: 7.640

2.  Fractionated 131I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice.

Authors:  J A Violet; J L J Dearling; A J Green; R H J Begent; R B Pedley
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.